Bicara Therapeutics initiated with a Not Rated at Goldman Sachs

Goldman Sachs initiated coverage of Bicara Therapeutics (BCAX) with a Not Rated, saying ficerafusp could beat pembro in first-line HPV-negative head and neck squamous cell carcinoma, “but has shortcomings” in the “race for best-in-class.”